
- Volume 0 0
MYLAN ACQUIRES INDIAN GENERIC DRUG MAKER MATRIX LABS
Mylan Laboratories moved into the international generic pharmaceutical market ina big way by announcing an agreement to acquire India's Matrix Labs. Under theagreement, Mylan will buy a 51.5% stake at Matrix under a complex formula thatcould drive the final cost as high as $736 million. Matrix Labs will remain a publiclytraded company in India and will continue to operate independently of Mylan.
Matrix Labs, one of the 12 companies authorized to supply medicines to formerPresident Bill Clinton's Clinton Foundation, is also one of India's leading suppliers ofraw materials for use by other generic pharmaceutical manufacturers in India.
Articles in this issue
over 19 years ago
Equation for Success: Diabetes Medication, Diet, and Exerciseover 19 years ago
Rx Product Newsover 19 years ago
OTC Product Newsover 19 years ago
can you READ these Rxs?over 19 years ago
Juvenile Anabolic Steroid Abuseover 19 years ago
Compounding Hotlineover 19 years ago
RESPy AWARD: A Role Model for Pharmacy Studentsover 19 years ago
Ouch! Time for Flu Shotsover 19 years ago
Supreme Court Declines to Review Generic Marketing PactsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.












































































































































































































